Evidence map›Paper›PMID 41089759›Full record

ArticleInternational journal of pharmaceutics: X2025

A self-delivery albumin nanomedicine amplified photodynamic therapy against esophageal cancer through COX-2/PGE2 interruption and regulation of mitochondrial respiratory.

Shiying Xu, Lina Wu, Boxin Chen, Xiaoliang Deng, Zhihui Zheng, Fei Wu, Lingjun Zeng, Changqing Zheng, Xiaomu Hu, Aiwen Huang and 3 more

Abstract read
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Hollow CuInternational journal of nanomedicine · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shiying XuSchool of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
Lina WuSchool of Biomedical Science, Huaqiao University, Quanzhou 362021, China.
Boxin ChenSchool of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
Xiaoliang DengDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Zhihui ZhengDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Fei WuDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Lingjun ZengDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Changqing ZhengDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Xiaomu HuDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Aiwen HuangDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Xin ZhouDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Xianquan FengFujian Provincial Key Laboratory of Transplant Biology Laboratory of Basic Medicine, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.
Zhihong LiuDepartment of Pharmacy, Fuzong Clinical College of Fujian Medical University (900th Hospital of PLA Joint Logistics Support Force), Fuzhou 350025, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) has emerged as a promising non-invasive cancer treatment due to its selective tumor ablation and excellent safety characteristics. However, its efficacy is limited by tumor hypoxia and excessive inflammation. In this study, we fabricated human serum albumin-based nanoparticles (CAI NPs) encapsulating celecoxib (CXB), atovaquone (ATO), and IR820

Indexed as

AtovaquoneCelecoxibEsophageal cancerIR820Photodynamic therapy

Identifiers

PMID41089759
PMCPMC12516533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.